Fifty years ago, a doctor diagnosing an underactive thyroid relied heavily on a clinical picture that had changed little since the nineteenth century: a slow pulse, a hoarse voice, a puffy face, a patient who complained of being cold while everyone else was comfortable. The blood tests now central to diagnosis existed, but they were crude and not always trusted. Today the sequence has reversed. Most patients are identified by a laboratory value before a physician ever notices their eyebrows thinning, and the central debate in thyroid medicine has shifted from how to detect the condition to what a mild laboratory abnormality actually means.
This reversal did not simplify the problem. It created a quieter question that now occupies endocrinologists, general practitioners and patients: when a test result is abnormal but a person feels broadly well, what is the right response? The answer, supported by a substantial body of research but still contested at the margins, shapes the care of millions of people worldwide.
A diagnosis once made at the bedside now hinges on a blood test
Hypothyroidism is the state in which the thyroid gland, a butterfly-shaped organ at the base of the neck, produces too little of the hormones thyroxine (T4) and triiodothyronine (T3). These hormones regulate the speed at which nearly every tissue in the body converts oxygen and nutrients into energy. When their supply falls, the body does not stop working; it slows.
Population surveys in iodine-sufficient countries generally find overt hypothyroidism, where hormone levels are clearly low, in about 0.3 to 0.5 percent of adults. Subclinical hypothyroidism, in which the pituitary hormone TSH is elevated but thyroid hormone levels remain within the normal range, is far more common, appearing in roughly 4 to 9 percent of adults depending on the cut-off used. The most common cause in iodine-rich regions is autoimmune thyroiditis, also called Hashimoto's disease, in which the immune system gradually damages the gland.
The signs and symptoms researchers keep returning to
The textbook list of hypothyroid symptoms is long because the hormones being replaced act on so many tissues. In clinical studies, the symptoms reported most often include persistent fatigue, unintended weight gain or difficulty losing weight, cold intolerance, constipation, dry skin, hair loss or coarsening, muscle aches, a slowed heart rate, heavy or irregular menstrual periods, depressed mood, and problems with memory or concentration. The American Thyroid Association offers a plain-language review of these symptoms and the underlying physiology for patients and clinicians.
The difficulty is that none of these symptoms is specific. Fatigue can result from poor sleep, stress, anaemia or depression; weight gain can reflect diet and activity; dry skin can accompany ageing. Large cohort studies have shown that a person with newly diagnosed overt hypothyroidism may have only a few of these complaints, while many people with normal thyroid function have several. That is why no symptom checklist alone has been able to replace biochemical testing.
Subclinical hypothyroidism: where the disagreement lies
Subclinical hypothyroidism is defined by a TSH value above the upper reference limit, typically around 4.0 to 4.5 milli-international units per litre, with a free T4 level still inside the normal range. Some patients in this zone describe symptoms that improve when levothyroxine is started. Some also have thyroid antibodies, which predict progression to overt disease. These are the two strongest arguments for treating: a plausible symptom burden and a measurable risk of the condition worsening.
The opposing argument is equally specific. Randomised trials in older adults have not found a convincing benefit of routine treatment for mild subclinical disease. In a 2017 trial published in the New England Journal of Medicine, researchers randomised 737 adults aged 65 and older with subclinical hypothyroidism to levothyroxine or placebo and found no meaningful difference in hypothyroid symptoms or fatigue after one year. The reason those findings have not ended the debate is that many clinicians treat selectively: for symptoms, for high antibody levels, for pregnancy or planned pregnancy, or for TSH values persistently above 10.
Photo by Sasun Bughdaryan on Unsplash
How the diagnosis is made
The standard first test is serum TSH. When the thyroid gland underperforms, the pituitary responds by releasing more TSH to stimulate it, so a high TSH is usually the first laboratory signal. If TSH is elevated, the next step is a free T4 measurement. A low free T4 confirms overt hypothyroidism; a normal free T4 places the patient in the subclinical category. Many clinicians also measure thyroid peroxidase antibodies when an autoimmune cause is suspected. The National Health Service describes the same two-test approach for adults in the United Kingdom.
Reference ranges are not identical everywhere. Some laboratories use upper TSH limits of 4.0, others 4.5 or 5.0, and pregnancy-specific ranges run lower. One early morning TSH result can be enough to diagnose overt disease, but mild elevations are often repeated after six to twelve weeks because TSH can return to normal on its own, particularly if the initial reading was only slightly above the cut-off.
Levothyroxine: the standard treatment, with precise details
For overt hypothyroidism, treatment is generally not contested. Synthetic levothyroxine, a manufactured form of T4, is taken once daily and restores the body's own hormone supply. The usual full replacement dose is around 1.6 micrograms per kilogram of body weight per day, though older adults and people with coronary artery disease often start lower and increase gradually. The goal is to bring TSH back into the normal range, which normally takes six to eight weeks to assess after any dose change.
Absorption details matter. Levothyroxine is best absorbed on an empty stomach, and many doctors recommend taking it 30 to 60 minutes before breakfast. Calcium supplements, iron tablets, proton pump inhibitors and certain foods can reduce absorption if taken too close together. Because the medication has a long half-life, a missed dose can be safely taken later in the day, but consistency matters more than perfection.
The liothyronine question
The thyroid gland normally releases both T4 and a smaller amount of T3. Levothyroxine relies on the body to convert T4 into T3 as needed. A minority of patients continue to feel unwell even when TSH is normal, and some patient groups argue that adding liothyronine, a synthetic T3, restores what replacement with T4 alone cannot. The argument has face plausibility because some tissues preferentially use T3 and because animal and human studies have shown that T4 monotherapy does not always reproduce the exact hormone ratio of an intact gland.
It does not follow, however, that every patient with residual symptoms should receive T3. A Cochrane systematic review has repeatedly concluded that the evidence does not support routine combination therapy. The trials included in those reviews show no consistent advantage for combined T4 and T3 treatment over levothyroxine alone for fatigue, mood, weight or quality of life. The question remains open mainly for a carefully defined subset of people who have normalised TSH but continue to have significant symptoms after other causes have been excluded.
Pregnancy, ageing and iodine: contexts that change the calculus
Pregnancy changes nearly every thyroid parameter. Thyroid hormone demand rises early in gestation, and international guidelines recommend trimester-specific TSH ranges. Untreated overt hypothyroidism in pregnancy is associated with a higher risk of miscarriage, preterm birth and impaired neurodevelopment in the child, which is why women with known hypothyroidism usually need an increased levothyroxine dose as soon as pregnancy is confirmed. The management of subclinical disease in pregnancy remains more cautious, but even modest TSH elevations are often treated when thyroid antibodies are present.
In older adults, the calculus tips the other way. Mild TSH elevations become more common with age, and over-replacement carries risks including atrial fibrillation and bone loss. Iodine deficiency remains an important cause of hypothyroidism in many parts of the world, and public health programmes that iodise salt have reduced the most severe consequences. In iodine-sufficient countries, however, most cases are autoimmune rather than nutritional. The World Health Organization publishes data on iodine status and the health consequences of deficiency for countries where this remains a public health concern.
Photo by iMattSmart on Unsplash
What the next guidelines will have to answer
The unresolved questions in hypothyroidism are less about whether to treat overt disease than about how far to extend treatment into the grey zone. Researchers are testing whether symptom scores, genetic markers or measures of thyroid hormone action can identify which people with mild TSH elevations actually benefit from medication. For patients who remain symptomatic on levothyroxine, the challenge is to distinguish true residual thyroid insufficiency from the many unrelated causes of fatigue.
Guideline committees in Europe, North America and elsewhere have reached broadly similar conclusions on levothyroxine as first-line therapy, but they differ in their thresholds for treating subclinical disease and in their willingness to recommend combination therapy. The next revisions will be watched closely because they will determine how aggressively a common and often lifelong condition is treated. Whether symptom response, rather than TSH normalisation alone, becomes the measured standard is the question those committees will now have to answer.